Centene Raises 2026 EPS Guidance Amid Medicaid Margin Gains

Centene Corporation has raised its 2026 adjusted earnings per share guidance to more than $4.80, reflecting faster-than-expected operating improvements in its Medicaid and Marketplace segments. Management noted that roughly 50 cents per share of the 2026 earnings will not recur in 2027 due to prior-year settlements, setting a distinct hurdle for future profitability.

The company’s stock has surged 57% year to date, outperforming the S&P 500’s 14.7% gain and significantly ahead of peers UnitedHealth Group Incorporated and Elevance Health, Inc., which returned 14% and 14.2%, respectively. This sharp rerating follows a difficult 2025, with investors now focused on whether recent margin gains can be sustained into 2027 rather than merely capturing recovery expectations.

Medicaid operations show measurable progress. The health benefits ratio improved to 93.9% in the second quarter, a 100 basis point improvement from the prior year. For the first half, the Medicaid HBR improved to 93.5% from 94.2%. Management expects full-year Medicaid HBR to settle near 93.5%, slightly better than its original 93.7% outlook. Rate increases are currently running slightly ahead of fundamental cost trends, aiding this trajectory, though membership losses and changing member acuity remain key risks.

The Marketplace segment has also strengthened. Centene raised its 2026 pretax-margin outlook for this business to 4.5-5%, driven by repricing and moderating medical trends. Second-quarter results benefited from roughly $180 million in favorable development tied to 2025 risk adjustment, a benefit that is unlikely to repeat. With 2027 products already being priced, investors are watching whether Centene can protect margins without sacrificing membership.

While earnings growth looks robust, top-line expansion is modest. The Zacks Consensus Estimate projects 2026 revenues of $196.29 billion, up just 0.8%, followed by a slight decline to $192.58 billion in 2027. Analysts expect 2026 earnings of $4.89 per share, a 135.1% increase from the previous year, and anticipate another 9.2% rise to $5.34 in 2027. Centene has exceeded earnings estimates in each of the past four quarters, with an average surprise of 151.3%.

Valuation metrics indicate Centene trades at 12.34X forward earnings, above its five-year median of 11.33X but below the industry average of 15.20X and peers UnitedHealth at 17.17X and Elevance Health at 13.84X. The stock carries a Value Score of A. However, capital efficiency lags the sector, with trailing 12-month return on capital at 6.8% compared to an industry average of 9.9%.

Cost pressures persist, with total operating expenses rising 6.6% year over year in the first half of 2026, following increases of 5.5% in 2023 and 5.8% in 2024. Because the firm relies heavily on government-sponsored healthcare programs, its financial results are sensitive to shifts in funding, reimbursement rules, and regulation across Medicaid, Medicare, and ACA Marketplace plans.